A novel near-infrared EGFR targeting probe for metastatic lymph node imaging in preclinical mouse models.

For the treatment of patients with oral squamous cell carcinoma (OSCC), the imaging of cervical lymph nodes and the evaluation of metastastic progression are of great significance. In recent years, the development of new non-radioactive lymph node tracers has been an area of intense research. Here, we report the synthesis, good biocompatibility, and in vivo evaluation of a new small molecule near-infrared (NIR) fluorescence probe by the conjugation of Lapatinib to S0456 (LP-S).

Simple pyrolysis of graphene-wrapped PtNi nanoparticles supported on hierarchically N-doped porous carbon for sensitive detection of carbendazim.

A novel electrochemical sensor was established based on graphene-wrapped PtNi nanoparticles supported on three-dimensional (3D) N-doped porous carbon (G-PtNi/3D-NPC) for the highly sensitive and selective detection of carbendazim (CBZ). In this sensing system, the encapsulation of PtNi nanoparticles (NPs) by graphene can effectively prevent the aggregation tendency and enhance the structural stability. The hierarchically porous nanostructures have a large specific surface area to expose a large number of active sites and the resulting enhanced electrical conductivity ultimate improves the electrocatalytic activity towards CBZ.

Plasma levels of soluble receptor for advanced glycation end products in Alzheimer's disease.

Background: A decreased plasma level of soluble form of the receptor for advanced glycation end products (sRAGE) in patients with Alzheimer's disease (AD) has been reported. However, no evidence has shown whether the sRAGE plasma level of AD patients may differentiate from other types of dementia.

Methods: Our study assessed sRAGE concentrations in the following 121 individuals in Chongqing area: 36 patients with AD, 12 with vascular dementia (VaD), 14 with mixed dementia (MD), 24 with other dementia (OD) including Parkinson's disease dementia, frontotemporal dementia, paralytic dementia and 35 cognitively normal controls.